Introduction: How does specialty pharmacy data quality affect life sciences companies?

Specialty pharmacy data underpins some of the most valuable commercial channel decisions that life sciences companies make: payer contracting, field force deployment, hub investment, and pull-through targeting. The stakes are high. Specialty drugs flow through an increasingly large and fragmented dispensing channel. In 2025, U.S. pharmacies dispensed an estimated $293.4 billion in specialty drugs.¹ Yet the channel generating this data has become harder to observe. More than 1,900 locations held specialty pharmacy accreditation in 2025, over five times the number in 2015.² Dispensing is spread across a growing number of sources that syndicated pharmacy data vendors must capture, even as manufacturers have narrowed distribution for many products. Of 382 specialty drugs with manufacturer-defined limited or exclusive networks in 2025, about one-third were dispensed by a single pharmacy.³ Thus, a single data-sharing relationship can largely determine how visible a product is in syndicated data offered by third-party data vendors.

As a result, the data underlying life sciences companies’ decisions is rarely as complete, precise, or accurate as the decisions themselves require. When the data falls short on any of these dimensions—whether through incomplete capture across fragmented dispensing channels, imprecise attribution of patients to payers as coverage shifts over time, or market distortions introduced by narrow networks and product blinding—the resulting outputs can skew the view of the market and mislead experienced analytic teams.

This paper aims to 1) frame these three key dimensions of syndicated specialty data quality—completeness, precision, and accuracy; 2) identify their root causes in the structure of the specialty pharmacy ecosystem; 3) outline a methodological approach for projecting, extrapolating, and validating specialty pharmacy data; 4) provide a solution framework for specialty pharmacy data curation; and 5) describe implementation steps for syndicated specialty pharmacy data quality monitoring so that commercial decisions rest on a sound analytic foundation rather than an incomplete one.

I. Framing the complexity of syndicated specialty pharmacy data quality

Specialty pharmacy data quality is not represented by a single metric. Although data quality can be described along many dimensions, three are most consequential for commercial decisions in specialty pharmacy and can be combined into an overall assessment. We define them as follows.

1. Completeness

   There is no single data source available to a life sciences company that captures the full picture of a complex system. In the specialty pharmacy ecosystem, completeness refers to the percentage of total real-world specialty pharmacy activity (such as prescriptions written, units dispensed, patients on therapy) that is captured in a given data asset. Knowing the gaps in a dataset is important for understanding its limitations. For example:

   • Closed claims datasets are valuable for adjudicated activity but lag in time and exclude cash-pay and patient-assistance volume.
   • Specialty pharmacy 867/852 transactions (e.g., electronic data interchange [EDI] standards for product resale and dispensing/inventory activity) are limited to the dispensing entities under contract and therefore capture only part of the channel.
   • Hub data (from the patient services hub that coordinates benefits verification, prior authorization, and financial assistance for a therapy) reflects only enrolled patients rather than all treated patients.
   • Wholesaler data reflects sell-in to the channel rather than sell-through to patients, so it does not capture what was actually dispensed.
   • Aggregated data may have blind spots for some specialty pharmacies or restricted channels, so the gap between observed volume and true volume is seldom zero and may not be quantified.


2. Precision

   Precision (used here in a domain-specific sense, not the statistical sense of reproducibility) refers to how well the observed activity is allocated to the right entity at the right time. Identifying the right payer at any given point in time is among the most critical. For example, a patient on a 12-month therapy may move from commercial insurance to Medicare upon turning 65; another may switch employers midyear. Some patients transition between primary and secondary coverage, or are served simultaneously by patient assistance programs, discount cards, and a payer. Snapshot views of payer mix mask this dynamism, especially within a single year. Static attribution in a dataset treats each prescription fill as if the patient’s coverage at that moment is the patient’s coverage for the year, which may not be true.

3. Accuracy

   Accuracy refers to whether the observed activity is a faithful representation of the underlying market, independent of whether it is complete. Two structural features of specialty drug distribution systematically distort what the data show: 1) narrow networks (such as limited distribution drug arrangements, exclusive specialty pharmacy contracts, and risk evaluation and mitigation strategy [REMS]-restricted channels) concentrate visibility in some entities and eliminate it in others; and 2) product blinding in aggregated data assets prevents identification of a product’s activity at the level of granularity needed for share-of-market and trend analysis. The result is that volume and performance metrics in restricted segments may appear stable, growing, or declining for reasons unrelated to actual market dynamics.

Data practitioners may view these three dimensions on a piecemeal basis rather than combine them, such that remediation efforts for perceived data deficits may address one dimension while leaving the others unaddressed. These errors can compound over time and can appear, for example, in contract terms that are a few points off, territories that are sized to the wrong volume, or pull-through campaigns that were delivered to the wrong providers.

II. Root causes of data quality gaps in the syndicated specialty pharmacy data used by life sciences companies

These three data dimensions are not attributes of any one data vendor or analytic team but instead represent the underlying organizational structure of the specialty pharmacy ecosystem itself. Inherent characteristics in the system create gaps in data quality that can result in incomplete evaluation strategies. Because these causes are structural rather than the fault of any one dataset, no single data source can eliminate them; they can only be managed analytically, which the following sections will address. These characteristics include the following.

• Channel fragmentation: Specialty therapies move through specialty pharmacies, hospital outpatient infusion centers, physician office buy-and-bill, home infusion, and limited-distribution arrangements. Each channel has its own data trail that is captured by different intermediaries under different contracts.
• Benefit design splits: Specialty therapies can straddle the pharmacy benefit and the medical benefit. Drugs billed under J-codes appear in medical claims with limited dispensing-event detail; drugs billed through the pharmacy benefit appear in National Drug Code (NDC)-level claims data.
• Patient identity fragmentation: In the absence of a universal patient identifier, linking events across data sources depends on tokenization, probabilistic matching, or trusted third parties, each of which introduces its own match rates and biases.
• Contractual and regulatory constraints: Limited-distribution contracts, narrow networks, gag provisions, and privacy (e.g., Health Insurance Portability and Accountability Act [HIPAA]) limitations on data linkage may restrict the data that can be aggregated and the granularity at which it can be reported. Some restrictions are intentional commercial design choices; others are compliance requirements.
• Time lags and revisions: Claims maturation varies by source and benefit type, and recent periods may be incomplete. Patient eligibility and coverage data are revised retrospectively. Snapshot analyses on recent periods systematically understate activity that has not yet been adjudicated.
• Aggregation rules: When third-party data assets blind small-volume cells, mask competitor products, or report at the geographic level rather than provider level, the published view is, by design, a degraded version of the underlying data.

III. Why specialty pharmacy data quality matters for commercial decision making at healthcare companies

Understanding these three dimensions can help reduce decision risk in commercial areas.

• Contracting: Payer contract terms (rebate offers, performance guarantees, and volume commitments) are calibrated to expected volume and patient mix. Imprecise payer attribution produces incorrectly calibrated terms, incomplete capture leads negotiators to underweight segments that are real but unmeasured, and channel-driven inaccuracy distorts perceived payer share. The resulting contracts can be financially material in either direction.
• Resource allocation: Field force sizing, hub investment, and patient services capacity are sized to observed patient volume and geographic distribution. Where narrow-network channels eliminate visibility, account-level deployment models can systematically under- or over-resource entire territories. Where capture is incomplete, hub capacity can be sized to observed enrollment rather than addressable enrollment.
• Pull-through: Pull-through depends on knowing where prescribers, patients, and payers intersect. When attribution lags coverage transitions, pull-through campaigns target the wrong payer's covered lives. When network restrictions blind channel volume, share-of-voice and share-of-prescription analyses miss the segment where the campaign needs to land.

In each risk scenario, the magnitude of decision error depends not on whether the data is “good” or “bad” in the abstract, but on whether the gap between observed and true has been characterized.

IV. A solution framework for specialty pharmacy data curation

Perfect data is not attainable in specialty pharmacy claims analysis. The realistic objective is to produce a defensible view of completeness, precision, and accuracy, and to incorporate that view into the decisions the data support. Three principles structure a sound approach to improving insights from the available data.

1. Triangulate across sources. No single data asset is sufficient. A defensible view requires consulting at least two and typically three of the following types: aggregated dispensing data, claims data, hub or patient services data, manufacturer distribution data, and primary research. Triangulation allows each source to anchor the others; gaps in one are filled by evidence from another.
2. Project to known anchors. Where total market size is known from independent sources (for example, total units shipped from manufacturer data), observed volume in a constrained data asset can be projected to estimate the total. Projection factors should be developed at the most granular level (e.g., channel, payer type, geography) at which a defensible anchor exists and is applied with explicit uncertainty bounds.
3. Model attribution as a process, not a snapshot. Payer attribution should be treated as a longitudinal estimation problem rather than a point-in-time lookup. For example, patient-month is a more defensible unit of analysis than patient-year for coverage-sensitive questions. Coverage transition rates should be estimated from data and applied prospectively.

V. Implementation steps for syndicated specialty pharmacy data quality monitoring

A practical approach to address syndicated specialty pharmacy data quality follows six steps.

1. Inventory the data. Catalog every data asset in use, internal and licensed, and document what each asset captures, what it does not, what its refresh cycle is, and what aggregation or blinding rules apply. This step alone reveals gaps that are typically invisible to individual analytic teams.
2. Map the gap. For each commercial decision supported by the data, identify which of the three dimensions (completeness, precision, accuracy) is most likely to drive error and by how much. The output is a heatmap of decisions versus dimensions, with rough magnitude estimates.
3. Establish anchors. Identify external reference points, manufacturer in-sell, published patient prevalence, hub enrollment counts, and REMS registrations, which can serve as anchors for projection. Document each anchor's reliability and the level of granularity at which it is usable.
4. Develop projection and attribution methods. Build the analytic methods: projection factors with explicit uncertainty, longitudinal payer attribution logic, channel-mix corrections for narrow-network distortion, blinding-aware competitive estimates. Record assumptions and methodology appropriately.
5. Validate against controls. Before deploying the data, validate it against held-out data and known historical outcomes. Where validation fails, refine; where it succeeds within tolerance, document.
6. Embed uncertainty in decisions. The final step is to build confidence intervals into the decisions themselves. Contract terms, resource allocations, and targeting plans should be stress-tested against the range of plausible market views, not optimized to the point estimate.

VI. Conclusion: Tips for life sciences companies navigating incomplete specialty pharmacy data

Syndicated specialty pharmacy data is structurally imperfect and is likely to remain so. The question is not whether to act on imperfect data (there is no alternative), but whether the imperfections have been characterized rigorously enough to support the decisions at stake. Organizations that treat completeness, precision, and accuracy as three distinct dimensions, address each with appropriate methodology, and embed the resulting uncertainty into commercial decisions are better positioned to make reliable, defensible decisions than those that treat the published number as definitive.

¹ Fein, A.J. (April 21, 2026). The top 15 specialty pharmacies of 2025: PBM-affiliated pharmacies dominate while health systems and independents gain ground. Drug Channels. Retrieved October 29, 2026, from https://www.drugchannels.net/2026/04/the-top-15-specialty-pharmacies-of-2025.html.

² Ibid.

³ Smaller pharmacies, bigger impact: Inside manufacturers’ specialty networks in 2025. (April 23, 2025). Drug Channels. Retrieved October 29, 2026, from https://www.drugchannels.net/2025/04/smaller-pharmacies-bigger-impact-inside.html.